PL2694075T3 - Inhibitor 3-kinazy fosfoinozytydowej z grupą wiążącą cynk - Google Patents

Inhibitor 3-kinazy fosfoinozytydowej z grupą wiążącą cynk

Info

Publication number
PL2694075T3
PL2694075T3 PL12764605.7T PL12764605T PL2694075T3 PL 2694075 T3 PL2694075 T3 PL 2694075T3 PL 12764605 T PL12764605 T PL 12764605T PL 2694075 T3 PL2694075 T3 PL 2694075T3
Authority
PL
Poland
Prior art keywords
phosphoinositide
kinase inhibitor
binding moiety
zinc binding
zinc
Prior art date
Application number
PL12764605.7T
Other languages
English (en)
Polish (pl)
Inventor
Xiong Cai
Haixiao Zhai
Chengjung Lai
Changgeng Qian
Rudi Bao
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of PL2694075T3 publication Critical patent/PL2694075T3/pl

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4365Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/16Amides, e.g. hydroxamic acids
    • A61K31/165Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/166Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/28Radicals substituted by singly-bound oxygen or sulphur atoms
    • C07D213/30Oxygen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D241/00Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/10Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D495/00Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PL12764605.7T 2011-04-01 2012-03-30 Inhibitor 3-kinazy fosfoinozytydowej z grupą wiążącą cynk PL2694075T3 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161470849P 2011-04-01 2011-04-01
US201161559489P 2011-11-14 2011-11-14

Publications (1)

Publication Number Publication Date
PL2694075T3 true PL2694075T3 (pl) 2016-09-30

Family

ID=46931927

Family Applications (2)

Application Number Title Priority Date Filing Date
PL16166266T PL3111938T3 (pl) 2011-04-01 2012-03-30 Inhibitor 3-kinazy fosfoinozytydowej z grupą wiążącą cynk
PL12764605.7T PL2694075T3 (pl) 2011-04-01 2012-03-30 Inhibitor 3-kinazy fosfoinozytydowej z grupą wiążącą cynk

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PL16166266T PL3111938T3 (pl) 2011-04-01 2012-03-30 Inhibitor 3-kinazy fosfoinozytydowej z grupą wiążącą cynk

Country Status (29)

Country Link
US (7) US8710219B2 (OSRAM)
EP (2) EP3111938B1 (OSRAM)
JP (3) JP6242331B2 (OSRAM)
KR (2) KR101902325B1 (OSRAM)
CN (2) CN105461736B (OSRAM)
AU (1) AU2012236367B2 (OSRAM)
BR (1) BR112013025340B1 (OSRAM)
CA (1) CA2830822C (OSRAM)
CL (1) CL2013002823A1 (OSRAM)
CY (2) CY1117785T1 (OSRAM)
DK (2) DK2694075T3 (OSRAM)
EA (1) EA022434B9 (OSRAM)
ES (2) ES2577982T3 (OSRAM)
HR (2) HRP20160545T1 (OSRAM)
HU (2) HUE028910T2 (OSRAM)
IL (2) IL228588A (OSRAM)
LT (1) LT3111938T (OSRAM)
ME (2) ME03523B (OSRAM)
MX (1) MX340577B (OSRAM)
PE (1) PE20141382A1 (OSRAM)
PL (2) PL3111938T3 (OSRAM)
PT (2) PT3111938T (OSRAM)
RS (2) RS59219B1 (OSRAM)
SG (2) SG193563A1 (OSRAM)
SI (2) SI2694075T1 (OSRAM)
SM (2) SMT201900435T1 (OSRAM)
TW (1) TWI571469B (OSRAM)
WO (1) WO2012135571A1 (OSRAM)
ZA (2) ZA201307082B (OSRAM)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2385832B1 (en) 2009-01-08 2015-07-15 Curis, Inc. Phosphoinositide 3-kinase inhibitors with a zinc binding moiety
PT3111938T (pt) 2011-04-01 2019-07-10 Curis Inc Inibidores de fosfoinoritide 3-quinase com uma fração de ligação ao zinco
CN103958497B (zh) 2011-11-14 2017-09-01 亚尼塔公司 作为AXL和c‑MET激酶抑制剂的尿嘧啶衍生物
CN104725301A (zh) * 2013-12-20 2015-06-24 北京蓝贝望生物医药科技股份有限公司 一种1,2-二氢吡啶-2-酮衍生物的制备方法
KR102015826B1 (ko) 2015-04-21 2019-08-29 구이저우 바이링 그룹 파마슈티컬 컴퍼니 리미티드 퓨리닐-n-하이드록실 피리미딘 포름아미드 유도체, 이의 제조 방법 및 용도
WO2018015895A1 (en) * 2016-07-19 2018-01-25 National Institute Of Plant Genome Research Novel protein against fungal pathogens
CA3040727A1 (en) * 2016-11-02 2018-05-11 Curis, Inc. Combination therapy with a phosphoinositide 3-kinase inhibitor with a zinc binding moiety
CN111801102B (zh) * 2017-11-06 2024-05-28 冷泉港实验室 用于形成含铜络合物的方法和组合物及其用途
CN113164466B (zh) 2018-09-11 2025-07-08 柯瑞斯公司 使用具有锌结合部分的磷酸肌醇3-激酶抑制剂的联合治疗
EP3968215A1 (en) 2020-09-09 2022-03-16 Koninklijke Philips N.V. Determining target object type and position
WO2023212574A1 (en) * 2022-04-26 2023-11-02 Olivia Szu Hsieh Lee Nakaya Compositions and methods for modulating rhythmic activity of pacemaker cardiomyocytes

Family Cites Families (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US4828991A (en) 1984-01-31 1989-05-09 Akzo N.V. Tumor specific monoclonal antibodies
US5369108A (en) 1991-10-04 1994-11-29 Sloan-Kettering Institute For Cancer Research Potent inducers of terminal differentiation and methods of use thereof
US5502187A (en) 1992-04-03 1996-03-26 The Upjohn Company Pharmaceutically active bicyclic-heterocyclic amines
US5497763A (en) 1993-05-21 1996-03-12 Aradigm Corporation Disposable package for intrapulmonary delivery of aerosolized formulations
US5508269A (en) 1994-10-19 1996-04-16 Pathogenesis Corporation Aminoglycoside formulation for aerosolization
US6777217B1 (en) 1996-03-26 2004-08-17 President And Fellows Of Harvard College Histone deacetylases, and uses related thereto
US6083922A (en) 1996-04-02 2000-07-04 Pathogenesis, Corp. Method and a tobramycin aerosol formulation for treatment prevention and containment of tuberculosis
US5767068A (en) 1997-02-13 1998-06-16 Pathogenesis Corporation Pure biologically active colistin, its components and a colistin formulation for treatment of pulmonary infections
EP1277738B1 (en) 2000-04-27 2011-03-30 Astellas Pharma Inc. Condensed heteroaryl derivatives
US6608053B2 (en) 2000-04-27 2003-08-19 Yamanouchi Pharmaceutical Co., Ltd. Fused heteroaryl derivatives
HRP20040801A2 (en) 2002-03-13 2005-04-30 Janssen Pharmaceutica N.V. Sulfonylamino derivatives as novel inhibitors of histone deacetylase
EP1485348B1 (en) 2002-03-13 2008-06-11 Janssen Pharmaceutica N.V. Carbonylamino-derivatives as novel inhibitors of histone deacetylase
US7205304B2 (en) 2002-03-13 2007-04-17 Janssen Pharmaceutica N.V. Sulfonyl-Derivatives as novel inhibitors of histone deacetylase
ATE425152T1 (de) 2002-03-13 2009-03-15 Janssen Pharmaceutica Nv Aminocarbonylderivate als histone-deacetylase- inhibitoren
AU2003255845A1 (en) 2002-08-22 2004-03-11 Piramed Limited Phosphadidylinositol 3,5-biphosphate inhibitors as anti-viral agents
EP1591446B1 (en) 2003-01-29 2013-03-06 Takeda Pharmaceutical Company Limited Thienopyrimidine compounds and use thereof
CA2561617A1 (en) * 2004-04-05 2005-10-20 Aton Pharma, Inc. Histone deacetylase inhibitor prodrugs
JP5213229B2 (ja) 2004-04-23 2013-06-19 エグゼリクシス, インコーポレイテッド キナーゼ調節因子および使用方法
JP4862654B2 (ja) 2004-10-08 2012-01-25 アステラス製薬株式会社 芳香環縮合ピリミジン誘導体
GB0423653D0 (en) 2004-10-25 2004-11-24 Piramed Ltd Pharmaceutical compounds
EP2522397A1 (en) 2005-02-03 2012-11-14 TopoTarget UK Limited Combination therapies using HDAC inhibitors
DK1885710T3 (en) 2005-05-18 2015-11-23 Janssen Pharmaceutica Nv SUBSTITUTED AMINOPROPENYLPIPERIDINE OR MORPHOLINE DERIVATIVES AS UNKNOWN INHIBITORS OF HISTONDEACETYLASE
CA2630717C (en) 2006-01-19 2015-02-24 Janssen Pharmaceutica N.V. Pyridine and pyrimidine derivatives as inhibitors of histone deacetylase
CN101370791B (zh) 2006-01-19 2012-05-02 詹森药业有限公司 作为组蛋白脱乙酰基酶抑制剂的吡啶和嘧啶衍生物
EP1981871B1 (en) 2006-01-19 2011-12-28 Janssen Pharmaceutica N.V. Heterocyclylalkyl derivatives as novel inhibitors of histone deacetylase
EP2046799B1 (en) 2006-04-26 2017-07-19 Genentech, Inc. Phosphoinositide 3-kinase inhibitor compounds and pharmaceutical compositions containing them
NZ572812A (en) 2006-04-26 2010-09-30 Hoffmann La Roche THIENO [3, 2-D] PYRIMIDINE Indazole DERIVATIVE USEFUL AS PI3K INHIBITOR
CL2007001167A1 (es) 2006-04-26 2008-01-25 Genentech Inc Compuestos derivados de pirimidina condensada, inhibidores de p13-quinasa; procesos para preparar los compuestos; composicion farmaceutica que los comprende; uso de los compuestos en la preparacion de medicamentos; proceso para preparar la composicion farmaceutica; y kit que incluye a la composicionfarmaceutica.
EP2018366A4 (en) 2006-05-16 2010-08-04 Univ Mcgill HYBRID MOLECULES WITH MIXED VITAMIN D RECEPTOR AGONISM AND HISTONDEACETYLASE RESISTANT PROPERTIES
KR101434164B1 (ko) 2006-09-11 2014-08-26 쿠리스 인코퍼레이션 아연 결합 부분을 함유한 퀴나졸린 계열 egfr 억제제
CA2663147A1 (en) 2006-09-11 2008-03-20 Curis, Inc. Substituted 2-indolinone as ptk inhibitors containing a zinc binding moiety
AU2007296743B2 (en) 2006-09-11 2012-02-16 Curis, Inc. Tyrosine kinase inhibitors containing a zinc binding moiety
US20080221132A1 (en) 2006-09-11 2008-09-11 Xiong Cai Multi-Functional Small Molecules as Anti-Proliferative Agents
US20080161320A1 (en) 2006-09-11 2008-07-03 Xiong Cai Fused bicyclic pyrimidines as ptk inhibitors containing a zinc binding moiety
US7547781B2 (en) 2006-09-11 2009-06-16 Curis, Inc. Quinazoline based EGFR inhibitors containing a zinc binding moiety
CN101573333B (zh) 2006-10-28 2013-06-12 梅特希尔基因公司 组蛋白脱乙酰酶抑制剂
WO2008073785A2 (en) 2006-12-07 2008-06-19 Genentech, Inc. Phosphoinositide 3-kinase inhibitor compounds and methods of use
JP5284977B2 (ja) 2006-12-07 2013-09-11 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト ホスホイノシチド3−キナーゼ阻害剤化合物及び使用方法
EP2120900A2 (en) 2007-02-15 2009-11-25 Novartis AG Combination of lbh589 with other therapeutic agents for treating cancer
US20080234332A1 (en) 2007-03-20 2008-09-25 Xiong Cai Raf kinase inhibitors containing a zinc binding moiety
WO2009036057A1 (en) 2007-09-10 2009-03-19 Curis, Inc. Antiproliferative agents containing a zinc binding moiety
TW200922564A (en) 2007-09-10 2009-06-01 Curis Inc CDK inhibitors containing a zinc binding moiety
TW200922590A (en) 2007-09-10 2009-06-01 Curis Inc VEGFR inhibitors containing a zinc binding moiety
WO2009036020A1 (en) 2007-09-10 2009-03-19 Curis, Inc. Mek inhibitors containing a zinc binding moiety
WO2009036066A1 (en) 2007-09-10 2009-03-19 Curis, Inc. Vegfr inhibitors containing a zinc binding moiety
PE20090678A1 (es) 2007-09-12 2009-06-27 Genentech Inc Combinaciones de compuestos inhibidores de fosfoinositida 3-quinasa y agentes quimioterapeuticos y los metodos de uso
WO2009042646A1 (en) 2007-09-24 2009-04-02 Curis, Inc. Anti-proliferative agents
WO2009055730A1 (en) 2007-10-25 2009-04-30 Genentech, Inc. Process for making thienopyrimidine compounds
US20090149511A1 (en) 2007-10-30 2009-06-11 Syndax Pharmaceuticals, Inc. Administration of an Inhibitor of HDAC and an mTOR Inhibitor
WO2009086012A1 (en) 2007-12-20 2009-07-09 Curis, Inc. Aurora inhibitors containing a zinc binding moiety
EP2311842A3 (en) 2008-06-24 2011-07-13 Takeda Pharmaceutical Company Limited PI3K/M TOR inhibitors
WO2009155659A1 (en) 2008-06-27 2009-12-30 The University Of Queensland Combination therapy
US8196911B2 (en) 2008-10-27 2012-06-12 Honda Motor Co., Ltd. Adjustable rate subframe mount
EP2385832B1 (en) * 2009-01-08 2015-07-15 Curis, Inc. Phosphoinositide 3-kinase inhibitors with a zinc binding moiety
WO2010089411A2 (en) 2009-02-09 2010-08-12 Universite De La Mediterranee Pd-1 antibodies and pd-l1 antibodies and uses thereof
MX2011009167A (es) 2009-03-12 2011-09-15 Genentech Inc Combinaciones de compuestos inhibidores de fosfoinositida 3-cinasa y agentes quimioterapeuticos para el tratamiento contra neoplasia hemotopoyeticas malignas.
PE20121816A1 (es) 2009-10-12 2013-01-02 Hoffmann La Roche Combinaciones de un inhibidor de pi3k y un inhibidor de mek
JP2013525308A (ja) 2010-04-16 2013-06-20 キュリス,インコーポレイテッド K−ras変異を有する癌の治療
PT3111938T (pt) * 2011-04-01 2019-07-10 Curis Inc Inibidores de fosfoinoritide 3-quinase com uma fração de ligação ao zinco
US20130102595A1 (en) 2011-04-15 2013-04-25 Curis, Inc. Treatment of cancers having k-ras mutations
TWI835048B (zh) 2011-08-01 2024-03-11 美商建南德克公司 利用pd-1軸結合拮抗劑及mek抑制劑治療癌症之方法
AU2016281622C1 (en) 2015-06-25 2021-11-18 Immunomedics, Inc. Combining anti-HLA-DR or anti-Trop-2 antibodies with microtubule inhibitors, PARP inhibitors, Bruton kinase inhibitors or phosphoinositide 3-kinase inhibitors significantly improves therapeutic outcome in cancer
CA3040727A1 (en) * 2016-11-02 2018-05-11 Curis, Inc. Combination therapy with a phosphoinositide 3-kinase inhibitor with a zinc binding moiety

Also Published As

Publication number Publication date
EP3111938B1 (en) 2019-05-08
ZA201307082B (en) 2015-04-29
CA2830822C (en) 2018-10-02
JP6275784B2 (ja) 2018-02-07
WO2012135571A1 (en) 2012-10-04
HUE028910T2 (en) 2017-01-30
HUE045041T2 (hu) 2019-12-30
PL3111938T3 (pl) 2019-09-30
KR20140023333A (ko) 2014-02-26
DK3111938T3 (da) 2019-07-01
SMT201900435T1 (it) 2019-09-09
HRP20160545T1 (hr) 2016-06-17
TW201247678A (en) 2012-12-01
ZA201406167B (en) 2015-03-25
EP2694075B1 (en) 2016-04-27
ES2577982T3 (es) 2016-07-19
US20200215039A1 (en) 2020-07-09
DK2694075T3 (en) 2016-08-01
MX340577B (es) 2016-07-13
KR101902325B1 (ko) 2018-09-28
EA022434B1 (ru) 2015-12-30
SG193563A1 (en) 2013-11-29
RS59219B1 (sr) 2019-10-31
US9657032B2 (en) 2017-05-23
TWI571469B (zh) 2017-02-21
US10543197B2 (en) 2020-01-28
ME03523B (me) 2020-04-20
CN105461736A (zh) 2016-04-06
US20170304279A1 (en) 2017-10-26
CL2013002823A1 (es) 2014-04-11
US20220168284A1 (en) 2022-06-02
NZ615586A (en) 2015-02-27
EP3111938A1 (en) 2017-01-04
IL248597B (en) 2018-04-30
HRP20191091T1 (hr) 2019-09-20
US11654136B2 (en) 2023-05-23
HK1194969A1 (zh) 2014-10-31
JP2018052987A (ja) 2018-04-05
PT3111938T (pt) 2019-07-10
US8710219B2 (en) 2014-04-29
MX2013011132A (es) 2014-03-12
CN103582483A (zh) 2014-02-12
US20190091211A1 (en) 2019-03-28
JP2014509653A (ja) 2014-04-21
EA022434B9 (ru) 2016-02-29
ME02451B (me) 2016-09-20
US20130090335A1 (en) 2013-04-11
SMT201600179B (it) 2016-08-31
CY1121825T1 (el) 2020-07-31
EP2694075A1 (en) 2014-02-12
BR112013025340A2 (pt) 2016-12-13
EA201301114A1 (ru) 2014-04-30
AU2012236367A1 (en) 2013-04-18
KR20180108848A (ko) 2018-10-04
IL228588A (en) 2016-11-30
US20160185796A1 (en) 2016-06-30
US11135205B2 (en) 2021-10-05
RS54903B1 (sr) 2016-10-31
AU2012236367B2 (en) 2014-10-09
JP6242331B2 (ja) 2017-12-06
SI2694075T1 (sl) 2016-07-29
US10111864B2 (en) 2018-10-30
JP2016188255A (ja) 2016-11-04
IL228588A0 (en) 2013-12-31
CY1117785T1 (el) 2017-05-17
CN103582483B (zh) 2016-02-17
IL248597A0 (en) 2016-12-29
PE20141382A1 (es) 2014-11-04
NZ705039A (en) 2016-03-31
ES2733128T3 (es) 2019-11-27
CN105461736B (zh) 2018-06-12
LT3111938T (lt) 2019-06-25
US20140243330A1 (en) 2014-08-28
US9249156B2 (en) 2016-02-02
PT2694075T (pt) 2016-07-11
SG10201602569RA (en) 2016-05-30
EP2694075A4 (en) 2014-10-01
BR112013025340B1 (pt) 2021-12-21
SI3111938T1 (sl) 2019-08-30
CA2830822A1 (en) 2012-10-04

Similar Documents

Publication Publication Date Title
IL237727A0 (en) Inhibitors of phosphoinositide 3-kinase with a zinc-binding group
IL248597A0 (en) A phosphoinositide-3-kinase inhibitor with a zinc binding site
GB2481513B (en) A magazine add-on
ZA201306639B (en) Attachment mechanism for a contaienr
GB201020236D0 (en) A composition for detecting biofilms on viable tissues
EP2611352A4 (en) DISHWASHER
PL2575543T3 (pl) Zestaw do konstruowania stelaża
GB201007327D0 (en) A fireseal
ZA201306307B (en) A fungicidal composition
GB201003609D0 (en) A phantom
GB201002966D0 (en) A bedchair
HUE056022T2 (hu) Eszköz egy fogaskerék rögzítésére
PL2385030T3 (pl) Kompozycja klejowa wolna od emisji
GB2484514B (en) A mechanism
GB201200412D0 (en) A rake
PL2611293T3 (pl) Nowa biocydowa kompozycja
AU332267S (en) A bumper guard
AU332323S (en) A bumper guard
GB201010041D0 (en) Drawer assembly for a vehicle
PH32010000120S1 (en) A rack
GB201116046D0 (en) A cover
GB201116008D0 (en) A kennel
PH32010000289S1 (en) A ballpen
GB201004308D0 (en) New inhibitor compounds